👉COSM is TODAY’S #1 ALERT*

Hey Folks, Jeff Bishop here,

A very interesting trade idea has come across my desk…

It’s a stock that had a big drawdown beginning in mid-October, but that finally found a floor in mid-December and has bounced from there.

💥Take a look at Cosmos Health Inc. (COSM)* on your trading platform.

You can see the stock had a 20%+ bounce on December 16 and has been trading in a pretty tight band from ~$0.45 to ~$0.55 ever since.

It’s sitting at the high end of that band right now, and if it breaks through resistance, we could see a serious rally play out.

Nothing guaranteed, of course, but I’m glued to COSM, today to see how it rides…

👉  COSM is TODAY’S #1 ALERT* 👈

COSM is a diversified, vertically-integrated global healthcare company featuring manufacturing, brands, and distribution all under one roof.

It owns and sells proprietary pharmaceutical and nutraceutical brands, and through its subsidiary Cana Laboratories, it manufactures medications, supplements, cosmetics, and medical devices under European GMP standards.

Beyond making products, COSM distributes a wide range of branded generic and OTC medicines to pharmacies and wholesale channels in Europe and the UK.

Here are the top 5 things to know:

1. Analysts are starting to pay attention, and with a big price target 🚀

Last Tuesday, Zacks Small-Cap Research initiated coverage on COSM, slapping a $4.50 per share valuation on it — more than 760% over Friday’s closing price.

Highlights Zacks sees:

• Revenue going from ~$64.4M in 2025 to ~$98.6M in 2026 and ~$130.8M in 2027. If that plays out, revenue will have more than doubled in two years.
• Improving margins and expansion into higher-value verticals like telehealth and AI R&D
• A vertically integrated portfolio spanning pharma, nutraceuticals, distribution, and tech.

The report concludes that COSM “is a rare opportunity for investors as a company that has solid revenue and expanding its core, while also growing its pharmaceutical business using advanced AI technology.”

2. It’s building a real healthcare platform, not just a single product 💊

Cosmos is a platform with actual revenue drivers in multiple categories:

• European GMP-certified manufacturing
• Distribution to pharmacies and wholesalers
• Proprietary nutraceutical brands Sky Premium Life and Mediterranation, and established pharmaceutical brands C-Sept and C-Scrub
• Pharma, OTC, and consumer health products.

This platform mindset is way more robust than a tiny biopharma that dies if one clinical fails, and it already is generating real revenue from diversified sources.

3. U.S. manufacturing means tariff dodging and scale potential 📈

In June 2025, COSM executed a deal to start U.S.-based GMP-certified (Good Manufacturing Practice) manufacturing through a partner, DolCas Biotech.

That’s a big strategic move because it mitigates tariff risk and opens up one of the largest consumer markets in nutraceuticals and branded products.

This means onshore production, better control, and better potential margins long term.

4. It’s marrying healthcare with tech 🧪

In January 2024, COSM acquired Cloudscreen, “a cutting-edge Artificial Intelligence (AI) powered platform” specializing in drug repurposing, “a process that involves uncovering new target proteins or indications for existing drugs for use in treating different diseases.”

With Cloudscreen, COSM is trying to uncover new uses for compounds and speed development. That’s a bucket normally reserved for biotech innovators with massive budgets.

That built on the company acquisition of ZipDoctor in April 2023. ZipDoctor is “a direct-to-consumer subscription-based telemedicine platform.”

5. It’s thinking outside healthcare with a crypto treasury strategy 🪙

On August 6, COSM announced “it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes … to support the launch of its Ethereum (ETH) digital asset treasury reserve strategy.” [emphasis added]

And on December 3, COSM revealed a long-term strategic partnership with Prime Ledger, “a leading provider of blockchain infrastructure services and digital asset treasury management.”

The agreement involves “a comprehensive digital transformation of Cosmos Health’s financial operations, including participating in the management of its $300,000,000 treasury facility and the tokenization of high-value intellectual property (IP).” [emphasis added]

Final Thoughts

As you do your own research, be sure to start with this investor presentation from last January and check out the company’s website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*ISSUER-SPONSORED DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received five thousand dollars (cash) from Cosmos Health Inc (via Prime Time Profiles) for a one day marketing program starting on January 20, 2026.

It might seem obvious, but while our client claims not to own any shares in Cosmos Health Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Cosmos Health Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.